EQS-News: Defence Therapeutics Inc. / Key word(s): Miscellaneous
DEFENCE'S INNOVATIVE THERAPEUTICS FEATURED ON VIEWPOINT WITH DENNIS QUAID
05.09.2023 / 08:00 CET/CEST
The issuer is solely responsible for the content of this announcement.

CSE: DTC
FSE: DTC
USOTC: DTCFF
PRESS RELEASE

DEFENCE'S INNOVATIVE THERAPEUTICS FEATURED ON VIEWPOINT WITH DENNIS QUAID

Vancouver, BC, Canada, September 5, 2023 - Defence Therapeutics Inc. (“ Defence ” or the“ Company ”) a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies is pleased to announce that Viewpoint, the educational television show distributed nationally and hosted by veteran actor
Dennis Quaid, is gearing up with content providers to share information regarding breakthroughs in biotechnology and highlight the transformative potential of cutting-edge therapeutics.

Hosted by acclaimed actor, Dennis Quaid, Viewpoint has engaged its audience by providing its viewers with unique and innovative content on a variety of topics. Defence, with its commitment to advancing healthcare through groundbreaking research and development, aims to amplify its reach and educate a wider audience about the latest advancements in biotechnology and their impact on improving human health. Viewpoint will feature cutting-edge research, clinical trials, and therapeutic innovations in the field of biotechnology conducted by Defence Therapeutics®.

The episode featuring Defence Therapeutics® will be distributed to 170+ stations throughout the U.S. on September 18, 2023, for their use as interstitial programming for one full year.
Defence Therapeutics® additionally created a commercial piece that is scheduled to air nationally on Fox Business Network on Thursday, September 7, 2023, during Primetime as well as on Sunday, September 10, 2023. U.S. Regional commercial w ill air 4 times in the Top 100 U.S. markets throughout the month of September 2023.

The team behind the Viewpoint episode also worked to create a broadcast educational documentary profile on Defence within the context of the feature story line, which includes interviews and topics related to Defence's proprietary Accum® technology and therapeutics innovations to fight cancer. The video is available on the following link: is an educational TV show distributed nationwide. The show is the receiver of several Telly awards. A cast of widely talented and diverse individuals anchor the program.

About Viewpoint with Dennis Quaid:

Viewpoint with Dennis Quaid is a highly acclaimed short-form series that offers insightful discussions on a wide range of topics. Hosted by renowned actor Dennis Quaid, the program provides unique perspectives through engaging content and expert guests. Viewpoint with Dennis Quaid aims to educate, inspire, and engage viewers by exploring important subjects and showcasing industry advancements.

About Defence:

Defence Therapeutics is a publicly-traded biotechnology company working on engineering the next generation vaccines and ADC products using its proprietary platform.
At the core of Defence Therapeutics platform lie two ground-breaking technologies, AccumTM and AccuTOXTM, which enable precision delivery of vaccine antigens or ADCs in their intact form to target cells and induce potent killing of cancer cells, respectively. As a result, increased efficacy and potency can be reached against catastrophic illness such as cancer and infectidiseases.

For further information:

Sebastien Plouffe, President, CEO and Director

P: (514) 947-2272

Cautionary Statement Regarding“Forward-Looking” Information

This release includes certain statements that may be deemed "forward-looking statements". All statements in this release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include regulatory actions, market prices, and continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.

Neither the CSE nor its market regulator, as that term is defined in the policies of the CSE, accepts responsibility for the adequacy or accuracy of this release.